H.R. 6501: Prescription Drug and Medical Device Price Review Board Act of 2016

Before you vote › Federal bills

H.R. 6501: Prescription Drug and Medical Device Price Review Board Act of 2016

114th Congress · introduced 2016-12-08 · Health · Latest: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

federal

Save to my notebook What does this mean? Print

Official title

Prescription Drug and Medical Device Price Review Board Act of 2016

Plain summary

Prescription Drug and Medical Device Price Review Board Act of 2016 This bill establishes the Prescription Drug and Medical Device Price Review Board within the Food and Drug Administration. Each manufacturer of a prescription drug or medical device that is sold in the United States must submit to the board: each type of prescription drug and medical device that it sells in the United States, or in a country that is a member of the Organization for Economic Co-operation and Development; the price charged by the manufacturer for the drug or device; and the costs of the manufacturer to produce them. The board must establish a formula for determining whether the average manufacturer price of a prescription drug or medical device over an annual quarter is an excessive price. Manufacturers may not charge excessive prices. Individuals may petition the board to determine whether the price for a prescription drug or medical device is excessive. The board may subject violators to reduced patent terms, civil penalties, and increased Medicaid rebates. The bill amends the Internal Revenue Code to impose a tax on the sale of prescription drugs or medical devices that have excessive prices. The board must allow individuals to import from approved counties prescription drugs and devices that are comparable to prescription drugs and devices with excessive prices.

Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.

What a vote does

PSI Sci description of the legislative step (not an opinion).

The strongest published arguments

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Rep. DeLauro, Rosa L. [D-CT-3] · 8 cosponsors

Cost estimate: No cost estimate published yet.

Cosponsors on this site

Janice D. Schakowsky (D-IL), Lloyd Doggett (D-TX), Gwen Moore (D-WI), Marcy Kaptur (D-OH), Peter Welch (D-VT)

Sponsor's campaign money: Rep. DeLauro, Rosa L. [D-CT-3] reported raising $1.6 million (2025–2026). Details. Shown for context only; it does not mean any donor supported this bill.

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Sources

• Congressional Research Service summary (Introduced in House)
• Congress.gov
• Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-114hr6501.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/114/hr>

Record fed-us-cong114-hr6501 · catalog fed-us-congress-bills-cong114 · updated 2026-11-15 by psicol fed-bills-cong114